Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Zura Bio has a consensus analyst rating of “Moderate Buy” from six research firms, with an average 12-month target price of $10.75.
• Recent analyst actions were mixed: Chardan raised its target to $11 and kept a buy rating, Wedbush initiated coverage with an outperform and $15 target, while Weiss Ratings reiterated a sell rating.
• The stock traded up 5.5% to $4.79, but the company still reported a quarterly EPS loss of ($0.22), missing expectations, and analysts now expect -0.63 EPS for the year.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $10.75.

ZURA has been the topic of a number of recent research reports. Chardan Capital increased their target price on Zura Bio from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, March 23rd. Wedbush initiated coverage on Zura Bio in a report on Monday, February 9th. They issued an "outperform" rating and a $15.00 target price on the stock. Oppenheimer cut their target price on Zura Bio from $16.00 to $15.00 and set an "outperform" rating on the stock in a report on Friday, March 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zura Bio in a report on Wednesday, April 8th.

Insiders Place Their Bets

In related news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the company's stock in a transaction on Thursday, February 26th. The shares were acquired at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the purchase, the insider owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 14.23% of the company's stock.

Hedge Funds Weigh In On Zura Bio

Large investors have recently bought and sold shares of the stock. Allworth Financial LP bought a new position in Zura Bio during the 4th quarter valued at $30,000. Scientech Research LLC bought a new position in Zura Bio during the 3rd quarter valued at $45,000. Dimensional Fund Advisors LP bought a new position in Zura Bio during the 4th quarter valued at $123,000. Squarepoint Ops LLC bought a new position in Zura Bio during the 3rd quarter valued at $109,000. Finally, Qube Research & Technologies Ltd bought a new position in Zura Bio during the 3rd quarter valued at $138,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Stock Up 5.5%

Shares of ZURA opened at $4.79 on Friday. Zura Bio has a 12-month low of $0.98 and a 12-month high of $7.44. The business's fifty day moving average is $5.94 and its 200 day moving average is $5.16. The stock has a market cap of $454.48 million, a P/E ratio of -4.39 and a beta of 0.09.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.05). On average, analysts expect that Zura Bio will post -0.63 EPS for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.